-

AstraZeneca boosts dividend despite flat revenue growth

AstraZeneca (LSE: AZN) announced a 7% increase in its annualised dividend for 2024, reflecting confidence in its financial performance and cash generation. The dividend will rise by 20 US cents to $3.10 per share. This …

AstraZeneca (LSE: AZN) announced a 7% increase in its annualised dividend for 2024, reflecting confidence in its financial performance and cash generation. The dividend will rise by 20 US cents to $3.10 per share.

This increase follows a year of significant profit growth for AstraZeneca. Pretax profit surged to $6.90 billion in 2023, up from $2.50 billion in 2022. However, revenue showed a modest 3.3% increase to $45.81 billion. Notably, a 21% jump in oncology revenue was offset by declines in other areas.

AstraZeneca’s strong financial position is bolstered by a significant reduction in cost of sales. The company slashed these costs by 33% in 2023, down to $8.27 billion from $12.39 billion.

The news of the dividend hike was met positively by investors, with AstraZeneca shares up 1.2% on Thursday morning.


Subscribe to Investomania for more AstraZeneca news and updates.

Sign up for Investomania

Subscribe to the Investomania newsletter to have our daily recap delivered directly to your inbox.

No spam. Unsubscribe anytime.